Crystalline form of eszopiclone, composition, preparation and uses thereof
The present invention discloses a crystalline form of S-zopiclone (Formula I) having a powder X-Ray diffraction spectrum excited by Cu-Ka radiation with characteristic peaks expressed in terms of 2θ at about 11.08°, about 12.38°, about 15.86°, about 17.88°, about 19. 98° and about 20.58°; a DSC thermogram with a peak at about 207.7° C. and an infrared absorption spectrum (IR) with characteristic peaks at about 3078 cm −1 , about 2942˜2838 cm −1 , about 2790 cm −1 , about 1716 cm −1 , about 1463 cm −1 , about 1372 cm −1 and about 757 cm −1 . The present invention also discloses a method for preparing the crystalline form of eszopiclone, its pharmaceutical composition and its use in preparing a medicament for treating sleep disorders.
1. A crystalline form of (S)-zopiclone having a powder X-ray diffraction pattern with characteristic peaks expressed in terms of 2θ at 11.08°, 12.38°, 15.86°, 17.88°, 19.98° and 20.58°; a differential scanning calormetry thermogram with a peak at 207.7° C. and an infrared absorption spectrum (IR) with characteristic peaks at 3078 cm −1 , 2942 to 2838 cm −1 , 2790 cm −1 , 1716 cm −1 , 1463 cm −1 , 1372 cm −1 and 757 cm −1 .
2. A process for preparing the crystalline form of (S)-zopiclone of claim 1 , the process comprises the following steps:
(a). dissolving (S)-zopiclone in ethyl acetate at a temperature ranging from 60° C. to a reflux temperature, wherein the ratio of the volume of ethyl acetate to the weight of (S)-zopiclone is from 10 mL 80 mL of ethyl acetate to 1 gram of (S)-zopiclone;
(b). allowing the solution to cool down to a temperature ranging from 30° C. to 50° C.;
(c). maintaining the solution at the temperature ranging from 30° C. to 50° C. for a period of 10 minutes to 12 hours;
(d). further cooling the solution to a temperature ranging from 10° C. to −10° C.;
(e). maintaining the solution at the temperature ranging from 10° C. to −10° C. for a period of 10 minutes to 12 hours; and
(f). isolating the crystalline form of (S)-zopiclone of claim 1 .
3. The process according to claim 2 , wherein in step (a), the ratio of the volume of ethyl acetate to the weight of (S)-zopiclone is from 25 mL to 50 mL of ethyl acetate to 1 gram of (S)-zopiclone; in step (b), the solution is allowed to cool to a temperature ranging from 35° C. to 45° C.; in step (c), the solution is maintained at the temperature ranging from 35° C. to 45° C. for a period of 1 hour to 6 hours; in step (d), the solution is further cooled to a temperature ranging from 5° C. to −5° C.; and in step (e), the solution is maintained at the temperature ranging from 5° C. to −5° C. for a period of 1 hour to 6 hours.
4. A pharmaceutical composition comprising the crystalline form of (S)-zopiclone of claim 1 and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition according to claim 4 , wherein one dosage unit of the pharmaceutical composition contains 1-15 mg of the crystalline form of (S)-zopiclone.
6. The pharmaceutical composition according to claim 5 , wherein one dosage unit of the pharmaceutical composition contains 3-12 mg of the crystalline form of (S)-zopiclone.
7. A method for treating sleep disorders, wherein the method comprises administering a therapeutically effective amount of the crystalline form of (S)-zopiclone of claim 1 to a subject in need thereof.
8. A method for treating sleep disorders, wherein the method comprises administering a therapeutically effective amount of any one of the pharmaceutical compositions of claims 4 - 6 to a subject in need thereof.